Skip to content

Bordetella pertussis IgG Control Serum BC120G

$94.00

Summary

  • Virion/Serion Diagnostic Kit Control for research use (RUO)
  • Bordetella pertussis IgG Control Serum
  • Applications: ELISA
  • IgG control serum
  • Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
  • 3 mL
Weight1 lbs
Dimensions9 × 5 × 2 in
target

Bordetella pertussis reactive IgG

species reactivity

Bordetella pertussis

applications

ELISA

assay type

Indirect & quantitative

available size

3 mL

Available product – Bordetella pertussis IgG Control Serum BC120G

kit
Research area
Infectious Disease
Storage
Store at 2-8°C.
Associated products
Bordetella pertussis Filamentous Hemagglutinin (FHA) Antigen (BA120VS3)
Bordetella pertussis Toxin Antigen (BA120VS4)
Bordetella pertussis whole cell Antigen (BA120VS8)
Bordetella pertussis Toxin Human IgA Assay Control (BC1201A)
Bordetella pertussis IgA Control Serum (BC120A)
Bordetella pertussis IgG Control Serum (BC120G)
Bordetella pertussis Toxin IgA ELISA Kit (ESR1201A)
Bordetella pertussis Toxin IgG ELISA Kit (ESR1201G)
Bordetella pertussis IgA ELISA Kit (ESR120A)
Bordetella pertussis IgG ELISA Kit (ESR120G)
Bordetella pertussis IgM ELISA Kit (ESR120M)
target relevance
Organism
Bordetella pertussis
Structure and strains
Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus of the genus Bordetella, and the causative agent of pertussis or whooping cough. Like B. bronchiseptica, B. pertussis can express a flagellum-like structure, even if it has been historically categorized as a nonmotile bacteria.[1] Its virulence factors include pertussis toxin, adenylate cyclase toxin, filamentous hemagglutinin, pertactin, fimbria, and tracheal cytotoxin.
Disease
Bordetella pertussis and Bordetella parapertussis are pathogens responsible for whooping cough, a worldwide spread infectious disease that is transmitted from person to person by droplet infection. Often young children up to four years old are affected. The mortality in infected infants is particularly high. Although young people and adults usually do not get seriously ill, they may act as a source of infection for non-protected and at risk patients such as infants and old people. Colonization of the respiratory tract and establishment of infection are facilitated by the synergistic action of several virulence factors.

Progression of a typical whooping cough can be divided into three stages. After an incubation period of one to two weeks symptoms begin with the catarrhal phase, usually accompanied by a cough, rhinitis and conjunctivitis. Subsequently, the convulsive phase follows characterized by paroxysmal cough attacks combined with vomiting of viscid mucus, laryngospasm and bronchospasm, leading to cyanosis in the child. After four to six weeks attacks diminish and slowly subside in the decrementi phase.
Detection and diagnosis
The ELISA technique is the most commonly chosen method for B. pertussis and B. parapertussis specific antibody determination in serodiagnosis and complements direct antigen detection. In over 90% of cases the IgG and IgA antibody responses are directed against the immunogens PT and FHA. Therefore, the SERION ELISA classic Bordetella pertussis IgG and IgA tests are based on antigen mixtures of PT and FHA. For the detection of IgM antibodies cellular bound lipopolysaccharid has outstanding diagnostic properties. Consequently, a whole-cell antigen preparation of B. pertussis is used in the SERION ELISA classic Bordetella pertussis IgM.

Data

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

pmidtitleauthorscitation

Protocols

relevant to this product
BC120G protocol

Documents

#
No results found

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.